US equities |
SPCX $166.92 ▲+5.01% NVDA $236.79 ▲+1.21% MU $1,064.52 ▼-0.97% TSLA $377.37 ▲+1.83% MSFT $525.47 ▲+1.53% SNDK $1,709.37 ▼-0.62% INTC $117.27 ▼-1.73% META $742.72 ▲+2.01%
FinancialContent

Articles published by Vaccinex, Inc.

News headline image
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports 2025 Annual Financial Results
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex, Inc. Announces Reverse Stock Split
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex Announces Pricing of $9.6 Million Public Offering
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX
News headline image
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
From Vaccinex, Inc.
Via GlobeNewswire
Tickers VCNX